OncoMed Pharmaceuticals

OncoMed Pharmaceuticals
Name	OncoMed Pharmaceuticals
Type	Public
Industry	Biotechnology
Founded	2004
Headquarters	Redwood City, California
Key people	Moussa Youdim, Martin Babich, Paul Hastings
Products	Monoclonal antibodies, targeted therapies
Num employees	~200 (peak)

OncoMed Pharmaceuticals was a biotechnology company focused on developing monoclonal antibodies and targeted therapies for oncology indications. Founded in 2004 and headquartered in Redwood City, California, the company pursued stem cell and cancer stem cell pathways with programs in colorectal, lung, pancreatic, and ovarian cancers. OncoMed engaged with pharmaceutical companies, academic institutions, and regulatory bodies while maintaining a portfolio of partnered and internally developed candidates.

History

OncoMed Pharmaceuticals was founded by executives and scientists with backgrounds at Genentech, Amgen, Genzyme, Stanford University, and University of California, San Francisco to commercialize cancer stem cell research emerging from work at Johns Hopkins University, Cold Spring Harbor Laboratory, and Dana–Farber Cancer Institute. Early financing involved venture capital firms such as Venrock, New Enterprise Associates, SV Life Sciences, and Atlas Venture. The company completed an initial public offering on the NASDAQ exchange, attracting investors including Fidelity Investments and New York Stock Exchange participants. Over its history OncoMed executed licensing agreements with multinational firms like GlaxoSmithKline, Bristol-Myers Squibb, and Roche; corporate strategy shifted with market conditions influenced by peers such as Celgene, Amgen, Gilead Sciences, and MedImmune. Executive leadership changes paralleled collaborations with academic centers including Harvard Medical School, University of Pennsylvania, Massachusetts Institute of Technology, and University of California, San Diego. Mergers and acquisitions activity in the biotech sector, involving companies like AstraZeneca, Pfizer, Eli Lilly and Company, and Sanofi, shaped the competitive landscape that OncoMed navigated until changes in funding and strategic priorities led to asset sales and program transfers to firms such as Ignyta and Zymeworks.

Corporate affairs

Corporate governance involved a board with members from investment firms like Sequoia Capital, Kleiner Perkins, and representatives of academic institutions including Columbia University, Yale University, and Brown University. Financial reporting conformed with standards overseen by Securities and Exchange Commission filings and interactions with auditors from firms such as PricewaterhouseCoopers and Deloitte. OncoMed maintained relationships with contract research organizations including Quintiles, Parexel, and Covance for clinical trial operations, and with contract manufacturing organizations like Lonza and Catalent for biologics production. Human resources and talent recruitment frequently drew from biotechnology hubs centered around Silicon Valley, Boston, San Francisco, and San Diego. Investor relations entailed outreach to institutional investors including BlackRock, Vanguard Group, and Goldman Sachs. Corporate counsel included firms with expertise in life sciences such as Goodwin Procter and Wilson Sonsini Goodrich & Rosati.

Research and development

OncoMed's R&D strategy concentrated on targeting cancer stem cell pathways identified through research from labs at Johns Hopkins University, Cold Spring Harbor Laboratory, and Stanford University School of Medicine. Programs targeted signaling cascades and receptors studied by researchers at Massachusetts Institute of Technology, Harvard Medical School, and University of California, San Francisco. Preclinical work utilized models developed at The Scripps Research Institute and Fred Hutchinson Cancer Research Center and employed technologies from providers like Illumina, Thermo Fisher Scientific, and Agilent Technologies. Clinical development involved phase I/II trials conducted under protocols designed with clinical investigators from Memorial Sloan Kettering Cancer Center, Mayo Clinic, Cleveland Clinic, and Johns Hopkins Hospital. Regulatory interactions occurred with Food and Drug Administration divisions and comparable agencies including European Medicines Agency and national competent authorities in markets such as United Kingdom, Germany, and Japan.

Products and pipeline

The pipeline comprised monoclonal antibodies and targeted biologics aimed at oncology indications similar to programs developed by Merck & Co., Novartis, and Bayer AG. Lead candidates included antibodies against pathways investigated by researchers at Stanford University, Harvard Medical School, and Dana–Farber Cancer Institute; several candidates reached phase I/II development with data presented at conferences such as American Society of Clinical Oncology, European Society for Medical Oncology, and American Association for Cancer Research. Manufacturing and formulation efforts leveraged partners like Lonza and Thermo Fisher Scientific; pharmacokinetic studies referenced methodologies from National Institutes of Health laboratories. While no marketed products were solely attributed to the company, assets transitioned to partners including GlaxoSmithKline, Celgene, and smaller biotechnology acquirers as part of strategic exits.

Collaborations and partnerships

OncoMed entered strategic collaborations with pharmaceutical companies and academic centers such as GlaxoSmithKline, Bristol-Myers Squibb, Celgene Corporation, Roche, Pfizer, ImmunoGen, Mersana Therapeutics, Leukemia & Lymphoma Society-funded projects, and research consortia involving Harvard University, MIT, and University of California, Berkeley. Clinical partnerships included networks like NCI Cancer Trials Network, European Organisation for Research and Treatment of Cancer, and academic cooperative groups at Dana–Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. Licensing deals and option agreements involved corporate counterparts such as GlaxoSmithKline and Sanofi; translational research collaborations connected investigators at Stanford Medicine, Yale School of Medicine, and Columbia University Medical Center.

Legal and regulatory matters

Regulatory oversight involved interactions with the Food and Drug Administration for Investigational New Drug applications and clinical trial approvals, and compliance with Securities and Exchange Commission reporting requirements following the company's public listing on NASDAQ. Intellectual property strategy depended on patents prosecuted with the assistance of law firms experienced before the United States Patent and Trademark Office and the European Patent Office, while litigation or disputes—typical in the biotechnology sector—entailed counsel familiar with precedent from cases involving Amgen, Genentech, and Biogen. Safety reporting and pharmacovigilance aligned with standards promoted by FDA guidance documents and pharmacovigilance frameworks used by multinational firms like Johnson & Johnson, Novartis, and Roche.

Category:Biotechnology companies